Latest News & Features
Genetics
ERS Genomics has agreed to license CRISPR-Cas9 technology to a Barcelona-based start-up which uses a zebrafish-based research model. 18 February 2021
Big Pharma
Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”. 16 February 2021
Americas
The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad. 16 February 2021
Americas
Cannabidiol retailer cbdMD is suing rival Majik Medicine over the latter’s use of the ‘CBD MD’ trademark, claiming it is confusing consumers. 15 February 2021
Big Pharma
Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year. 15 February 2021
Americas
A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code. 11 February 2021
Big Pharma
Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment. 11 February 2021
Big Pharma
China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug. 11 February 2021
article
Patents and other forms of IP have traditionally been the main way pharmaceutical and biotech companies have secured markets and ensured freedom to operate. 2020 has seen a shift towards licensing deals from some of the leading names in Life Sciences, will this trend continue? 11 February 2021
Big Pharma
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report. 10 February 2021